Coya Therapeutics has progressed COYA 302 into an active-treatment extension phase of its Phase 2 ALS trial, where all participants now receive the investigational therapy—a combination of low-dose interleukin-2 and CTLA-4 Ig designed to modulate regulatory T cell function and reduce neuroinflammatory responses. This advancement extends safety and efficacy observation to 48 weeks, providing critical data on whether immune modulation can slow neurodegeneration in ALS.
Key Points
- COYA 302 combines IL-2 and CTLA-4 Ig to enhance regulatory T cells
- Extension phase allows 48 weeks total observation across dosing regimens
- Targets monocyte and macrophage-driven neuroinflammation in ALS
Longevity Analysis
Neuroinflammation represents a central driver of neurodegenerative disease progression, and interventions that suppress pathogenic immune activation while preserving protective immunity address a fundamental mechanism of aging-related neuronal loss. The extension of COYA 302 into active treatment phase signals that immune tolerance strategies—specifically regulatory T cell enhancement—may interrupt the cascade of microglial and macrophage activation that characterizes ALS and other proteopathies. Success here would validate a broader approach to aging: identifying and interrupting the molecular signals that drive aberrant immune responses rather than simply replacing lost function.
Original published by LT Wire.